Another Dupixent approval in the EU

French pharma major Sanofi’s (Euronext: SAN) Dupixent (dupilumab), which notched up sales of 3.5 billion euros ($3.8 billion) in third-quarter 2024, +23.8% year-on-year, has picked up yet another indication in collaboration with Regeneron (Nasdaq: REGN).

The European Medicines Agency (EMA) has approved Dupixent to treat eosinophilic esophagitis (EoE) in children as young as one year of age.

Specifically, the approval covers children aged one to 11 years who weigh at least 15 kg and who are inadequately controlled by, intolerant to, or who are not candidates for conventional medicinal therapy.